If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
The collaboration between CARER and Wholeleaf aims to offer an integrated approach to cancer patients, combining services and products to optimize their well-being
The strategic acquisition demonstrates the company’s commitment to increasing OTC consumer convenience in eye care
Approval to dramatically change CAR-T therapies landscape
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
_256_384.jpg)
The collaboration aims to raise awareness about eye cancer, provide medical and surgical treatment support to children and supply nutritional supplements to aid in their faster recovery.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
Subscribe To Our Newsletter & Stay Updated
